BD HorizonTM BV786 Biosimilar Anti-Human CD20

Description

Two-color flow cytometric analysis of Human CD20 Obinutuzumab Biosimilar expression on Human peripheral blood lymphocytes. Human whole blood was treated with BD Pharm Lyse Lysing Buffer Cat. No. 555899 to lyse erythrocytes. The leukocytes were washed, preincubated with BD Pharmingen Human BD Fc Block Cat. No. 564219 and stained with PE Mouse Anti-Human CD19 antibody Cat. No. 555413 and with either BD OptiBuild BV786 Human IgG1 N297A , kappa Isotype Control Cat. No. 756236; Left Plot or BD Horizon BV786 Biosimilar Anti-Human CD20 Obinutuzumab Biosimilar antibody Cat. No. 570973/571044; Right Plot . The bivariate pseudocolor density plot showing the correlated expression of CD20 or Ig Isotype control staining versus CD19 was derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometric analysis was performed using a BD Fortessa X-20 Flow Cytometer System and FlowJo Software. Multiparameter flow cytometric analysis of Human CD20 Obinutuzumab Biosimilar expression on Human peripheral blood leukocytes. Human whole blood was treated with BD Pharm Lyse Lysing Buffer Cat. No. 555899 to lyse erythrocytes. The leukocytes were washed, preincubated with BD Pharmingen Human BD Fc Block Cat. No. 564219 and stained with either BD OptiBuild BV786 Human IgG1 N297A , kappa Isotype Control Cat. No. 756236; Left Plot or BD Horizon BV786 Biosimilar Anti-Human CD20 Obinutuzumab Biosimilar antibody Cat. No. 570973/571044; Right Plot . The bivariate pseudocolor density plot showing the correlated expression of CD20 or Ig Isotype control staining versus side light-scatter SSC-A signals was derived from gated events with the forward and side light-scatter characteristics of viable leukocyte populations. Flow cytometric analysis was performed using a BD Fortessa X-20 Flow Cytometer System and FlowJo Software. Two-color flow cytometric analysis of Human CD20 Obinutuzumab Biosimilar expression on Human peripheral blood lymphocytes. Human whole blood was treated with BD Pharm Lyse Lysing Buffer Cat. No. 555899 to lyse erythrocytes. The leukocytes were washed, preincubated with BD Pharmingen Human BD Fc Block Cat. No. 564219 and stained with PE Mouse Anti-Human CD19 antibody Cat. No. 555413 and with either BD OptiBuild BV786 Human IgG1 N297A , kappa Isotype Control Cat. No. 756236; Left Plot or BD Horizon BV786 Biosimilar Anti-Human CD20 Obinutuzumab Biosimilar antibody Cat. No. 570973/571044; Right Plot . The bivariate pseudocolor density plot showing the correlated expression of CD20 or Ig Isotype control staining versus CD19 was derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometric analysis was performed using a BD Fortessa X-20 Flow Cytometer System and FlowJo Software. Show More Multiparameter flow cytometric analysis of Human CD20 Obinutuzumab Biosimilar expression on Human peripheral blood leukocytes. Human whole blood was treated with BD Pharm Lyse Lysing Buffer Cat. No. 555899 to lyse erythrocytes. The leukocytes were washed, preincubated with BD Pharmingen Human BD Fc Block Cat. No. 564219 and stained with either BD OptiBuild BV786 Human IgG1 N297A , kappa Isotype Control Cat. No. 756236; Left Plot or BD Horizon BV786 Biosimilar Anti-Human CD20 Obinutuzumab Biosimilar antibody Cat. No. 570973/571044; Right Plot . The bivariate pseudocolor density plot showing the correlated expression of CD20 or Ig Isotype control staining versus side light-scatter SSC-A signals was derived from gated events with the forward and side light-scatter characteristics of viable leukocyte populations. Flow cytometric analysis was performed using a BD Fortessa X-20 Flow Cytometer System and FlowJo Software. Show More Two-color flow cytometric analysis of Human CD20 Obinutuzumab Biosimilar expression on Human peripheral blood lymphocytes. Human whole blood was treated with BD Pharm Lyse Lysing Buffer Cat. No. 555899 to lyse erythrocytes. The leukocytes were washed, preincubated with BD Pharmingen Human BD Fc Block Cat. No. 564219 and stained with PE Mouse Anti-Human CD19 antibody Cat. No. 555413 and with either BD OptiBuild BV786 Human IgG1 N297A , kappa Isotype Control Cat. No. 756236; Left Plot or BD Horizon BV786 Biosimilar Anti-Human CD20 Obinutuzumab Biosimilar antibody Cat. No. 570973/571044; Right Plot . The bivariate pseudocolor density plot showing the correlated expression of CD20 or Ig Isotype control staining versus CD19 was derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometric analysis was performed using a BD Fortessa X-20 Flow Cytometer System and FlowJo Software. Multiparameter flow cytometric analysis of Human CD20 Obinutuzumab Biosimilar expression on Human peripheral blood leukocytes. Human whole blood was treated with BD Pharm Lyse Lysing Buffer Cat. No. 555899 to lyse erythrocytes. The leukocytes were washed, preincubated with BD Pharmingen Human BD Fc Block Cat. No. 564219 and stained with either BD OptiBuild BV786 Human IgG1 N297A , kappa Isotype Control Cat. No. 756236; Left Plot or BD Horizon BV786 Biosimilar Anti-Human CD20 Obinutuzumab Biosimilar antibody Cat. No. 570973/571044; Right Plot . The bivariate pseudocolor density plot showing the correlated expression of CD20 or Ig Isotype control staining versus side light-scatter SSC-A signals was derived from gated events with the forward and side light-scatter characteristics of viable leukocyte populations. Flow cytometric analysis was performed using a BD Fortessa X-20 Flow Cytometer System and FlowJo Software.